Form S-3ASR CRISPR Therapeutics AG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
August 6, 2024 6:43 AM EDTRBC Capital analyst Luca Issi lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $60.00 (from $66.00) while maintaining a Sector Perform rating.
The analyst comments "Casgevys launch is under way with >35 ATCs activated (vs >25 last Q) and cells collected from 20... More
